Illumina's Growth Challenges: A Rollercoaster Ride with Grail

Illumina, established in 1998, has long been regarded as a dominant player in the global genomics sequencing field. However, recent years have seen its market position in China, for example, being challenged. In 2020, Illumina faced competition as BGI Genomics captured 12.6% of the domestic market share, while Illumina maintained a 58.6% share. Furthermore, Illumina experienced its first revenue decline in a decade, with a decrease of 9% to $3.239 billion in 2020 from $3.543 billion in 2019. Net profits also dropped by 37.58% to $656 million. In response, Illumina focused on fortifying its core sequencing business while exploring downstream opportunities for growth.

Fortifying the Core Business:
Illumina has continuously deepened its commitment to the core sequencing business, establishing a wide ecosystem and consistently upgrading sequencing equipment to solidify its competitive edge. For instance, the recently launched NovaSeqX has significantly reduced sequencing costs to around $200. In the sequencing industry, cost directly translates to competitiveness, and Illumina's efforts to drive down costs have been pivotal.

Exploring Downstream Opportunities:
To find new avenues for growth, Illumina has been accelerating its exploration of downstream opportunities. In 2021, the company acquired Grail, a leading global cancer screening company, for a staggering $8 billion. It is worth noting that Illumina had initially established Grail as an independent entity in 2016, but retained minority equity while allowing Grail to raise funds and develop its products. With the inclusion of Grail, Illumina estimates that the market size for the genomics sequencing industry will increase to approximately $60 billion by 2030. However, the acquisition of Grail has incurred losses for Illumina without any immediate gains.

Challenges Faced:
Illumina's journey with Grail has not been without challenges. Firstly, the company faced substantial fines. Illumina swiftly completed the acquisition before obtaining approval from antitrust authorities in the EU and the United States. In July 2023, the European Commission imposed a record-breaking fine of $476 million on Illumina, while Grail received a symbolic fine of $1,100.

Additionally, Illumina has made significant operating investments. Grail's core pipeline is in large-scale prospective clinical stages, requiring substantial funds. Since 2021, total operating expenses have reached $1.87 billion. As of June 2022, Illumina had a cash balance of $633 million, indicating that a significant portion of Grail's operating expenses has been covered by Illumina. Even considering only the operating expenses for Grail in 2022 and 2023, the amount totals $980 million.

Moreover, Illumina has faced substantial impairment losses. The decline in capital markets since 2021 has impacted Illumina's acquisitions. Specifically, there have been impairment losses of $3.914 billion in 2022 and $821 million from 2023 to the present, totaling $4.73 billion.

Furthermore, Illumina has experienced a significant decline in market capitalization. Prior to the Grail acquisition, Illumina maintained a net profit margin of 20-30% and was among the top performers in the medical device and diagnostics industry. In 2021, its market capitalization surpassed $70 billion. However, after the acquisition, Illumina's stock price plummeted from its peak of $555.77 to a low of $89, making it one of the worst-performing medical companies. As of the latest stock price, Illumina's market capitalization has evaporated by over $50 billion. Currently, Illumina is unable to wait for the full realization of Grail's value.

On December 18th, Illumina officially announced the spin-off of Grail, with an expected completion no later than the second quarter of 2024. Interestingly, upon the news of the spin-off, Illumina's stock price surged by 8.08%. Illumina's strategic journey with Grail has been a rollercoaster ride, marked by fines, substantial operating investments, impairment losses, and a significant decline in market capitalization. As the company moves forward with the spin-off, it aims to navigate the challenges and unlock new growth opportunities in the ever-evolving genomics sequencing industry.